Evidence map›Paper›PMID 42045944›Full record

ReviewJournal of nanobiotechnology2026

Lipid nanoparticles for bone marrow-targeted RNA therapeutics.

L D Mata Casimiro, R Escudero, M du Plessis, R Schiffelers, O Heidenreich

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

L D Mata CasimiroPrinses Maxima Centrum for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.
R EscuderoPrinses Maxima Centrum for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.
M du PlessisPrinses Maxima Centrum for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.
R SchiffelersCDL Research, University Medical Center Utrecht, Utrecht, The Netherlands.
O HeidenreichPrinses Maxima Centrum for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands. o.t.heidenreich@prinsesmaximacentrum.nl.

Funding

Health Holland HH-PPS-24061-PC-H027Stichting Kinderen Kankervrij 329
6 · The paper itself

Abstract

Lipid nanoparticle (LNP)-mediated delivery of therapeutic RNA molecules to the bone marrow (BM) holds transformative potential to treat hematological malignancies such as leukemia and for advancing immune and regenerative therapies. Despite this promise, LNPs exhibit poor BM accumulation following systemic administration. Formidable physiological barriers including rapid clearance by the mononuclear phagocyte system, predominant off-target sequestration in the liver, complement activation and inefficient endosomal escape currently limit their efficacy for extrahepatic applications. This review characterizes the complex BM physiology and the multifaceted challenges hindering LNP delivery to this organ. We discuss successful in vivo passive and active targeting strategies, evaluate emerging preclinical in vitro models and highlight innovative LNP design strategies aimed at enhancing particle stability and circulation time. Together, these advances establish a framework for the next-generation of RNA-therapeutics dedicated to treating BM-associated diseases.

Indexed as

Bone MarrowLipidsNanoparticlesRNAAnimalsHumansLiposomesLipid NanoparticlesLipidsLiposomesRNABone marrowGene therapyLipid nanoparticle (LNP)RNA therapeuticsTargeting

Identifiers

PMID42045944
PMCPMC13273966

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.